A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.

MLA

Cohen, Jonathon B., et al. “A Phase 2 Trial of Alisertib in Patients with Relapsed or Refractory B-Cellnon-Hodgkin Lymphoma.” Leukemia & Lymphoma, vol. 58, no. 9, Sept. 2017, pp. 1–2. EBSCOhost, https://doi.org/10.1080/10428194.2017.1289527.

APA

Cohen, J. B., Maddocks, K. J., Huang, Y., Christian, B. A., Jaglowski, S. M., Flowers, C. R., & Blum, K. A. (2017). A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. Leukemia & Lymphoma, 58(9), 1–2. https://doi.org/10.1080/10428194.2017.1289527

Chicago

Cohen, Jonathon B, Kami J Maddocks, Ying Huang, Beth A Christian, Samantha M Jaglowski, Christopher R Flowers, and Kristie A Blum. 2017. “A Phase 2 Trial of Alisertib in Patients with Relapsed or Refractory B-Cellnon-Hodgkin Lymphoma.” Leukemia & Lymphoma 58 (9): 1–2. doi:10.1080/10428194.2017.1289527.